List view / Grid view
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson's disease (PD).
The glaucoma drug methazolamide removed tau build-up and lessened signs of dementia in genetically-engineered zebrafish and mice.
The study identified which specific HERVs are important in increasing susceptibility for neurodegenerative diseases.
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
Findings show that alpha-synuclein and an immune response are required for Lewy body formation, in an effect specific to dopaminergic neurons.
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
Mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models.
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
A synthetic antibody selectively activates the Wnt signalling pathway and directs stem cells to differentiate into neurons.
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
A condensed version of the SMN2 gene could improve discovery of potential therapies for spinal muscular atrophy and other conditions.
Researchers have found that using protein-like polymers to inhibit the Keap1/Nrf2 PPI is a powerful therapeutic strategy.
